Who are nicotinic acid/laropiprant's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nicotinic-acid-laropiprant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

nicotinic acid/laropiprant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

nicotinic acid/laropiprant (nicotinic acid/laropiprant) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipid-modifying agent / Antilipemic. Area: Cardiovascular.

marketed Lipid-modifying agent / Antilipemic GPR109A receptor (laropiprant component); nicotinic acid acts on multiple lipid metabolism pathways Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

nicotinic acid/laropiprant (nicotinic acid/laropiprant) — Manchester University NHS Foundation Trust. Nicotinic acid raises HDL cholesterol and lowers triglycerides and LDL cholesterol, while laropiprant blocks the niacin flush response by antagonizing the GPR109A receptor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
nicotinic acid/laropiprant TARGET	nicotinic acid/laropiprant	Manchester University NHS Foundation Trust	marketed	Lipid-modifying agent / Antilipemic	GPR109A receptor (laropiprant component); nicotinic acid acts on multiple lipid metabolism pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipid-modifying agent / Antilipemic class)

Manchester University NHS Foundation Trust · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). nicotinic acid/laropiprant — Competitive Intelligence Brief. https://druglandscape.com/ci/nicotinic-acid-laropiprant. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing